Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 29;13(3):782.
doi: 10.3390/jcm13030782.

Platelet-Rich Plasma for Patients with Olfactory Dysfunction: Myth or Reality? A Systematic Review

Antonio Moffa  1   2 , Domiziana Nardelli  2 , Lucrezia Giorgi  1   3 , Simone Di Giovanni  1   2 , Luca Carnuccio  2 , Carmen Mangino  2 , Peter Baptista  4   5 , Michele Vacca  6 , Manuele Casale  1   2
Affiliations
Review

Platelet-Rich Plasma for Patients with Olfactory Dysfunction: Myth or Reality? A Systematic Review

Antonio Moffa et al. J Clin Med. .

Abstract

Background: With promising outcomes, platelet-rich plasma (PRP) has recently been suggested as a treatment for olfactory dysfunction (OD).

Methods: Clinical studies utilizing PRP in OD caused by COVID-19, trauma, anesthetic exposure, viral infection, and chronic rhinosinusitis were included in a systematic review.

Results: Ten clinical studies were qualitatively analyzed. Six of these studies used the PRP for OD caused by COVID-19, one on OD after functional endoscopic sinus surgery, and three on post-infectious or post-trauma OD. The population included 531 patients, ranging in age from 15 to 63.

Conclusion: The use of PRP may be a risk-free and efficient therapeutic option with very encouraging outcomes. Indeed, it enhances olfactory perception in patients who not only exhibit COVID-19 infection aftereffects, but also in those who have lost their sense of smell due to trauma, rhinosinusitis, rhinitis, or even surgery. To evaluate the PRP's therapeutic benefits in OD patients and to compare the efficacy of different therapeutic protocols with regard to treatment schedules, there is an urgent need for focused controlled trials.

Keywords: COVID-19; anosmia; olfactory dysfunction; platelet-rich plasma; smell loss.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flowchart outlining the paper selection process of the systematic review (based on PRISMA guidelines).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Croy I., Nordin S., Hummel T. Olfactory disorders and quality of life–An updated review. Chem. Senses. 2014;39:185–194. doi: 10.1093/chemse/bjt072. - DOI - PubMed
    1. Whitcroft K., Altundag A., Balungwe P., Boscolo-Rizzo P., Douglas R., Enecilla M., Fjaeldstad A., Fornazieri M., Frasnelli J., Gane S., et al. Position paper on olfactory dysfunction: 2023. Rhinology. 2023;61:1–108. doi: 10.4193/Rhin22.483. - DOI - PubMed
    1. Agyeman A.A., Chin K.L., Landersdorfer C.B., Liew D., Ofori-Asenso R. Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis. Mayo Clin. Proc. 2020;95:1621–1631. doi: 10.1016/j.mayocp.2020.05.030. - DOI - PMC - PubMed
    1. Rocke J., Hopkins C., Philpott C., Kumar N. Is loss of sense of smell a diagnostic marker in COVID-19: A systematic review and meta-analysis. Clin. Otolaryngol. 2020;45:914–922. doi: 10.1111/coa.13620. - DOI - PMC - PubMed
    1. Alkholaiwi F.M., Altamimi A.F., Almalki H.H., Almughaiseeb F.A., Alsubaie S.S., Alsayahi H.S., Alhijli F.W., Alobaishi R.S., Agrawal A., Alqahtani Z.A., et al. Olfactory dysfunction among patients with COVID-19. Saudi Med. J. 2023;44:1085–1103. doi: 10.15537/smj.2023.44.11.20230264. - DOI - PMC - PubMed